Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:07 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 190 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Urine Marker Clear all

Conditions: Male Breast Cancer, Neurotoxicity, Peripheral Neuropathy, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions: laboratory biomarker analysis, questionnaire administration; Other
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 2
States / cities: Paoli, Pennsylvania • Philadelphia, Pennsylvania

Conditions: Bladder Cancer
Interventions: Registry; Other
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2035
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Huntington Disease
Interventions: computer vision, remote monitoring, blood, urine, wrist bands, mobile-app; Diagnostic Test
Lead sponsor: Stanford University; Other
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2035
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: PSA, Prostate Cancer
Interventions: MRI prostate; Diagnostic Test
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older · Male only
Enrollment: 950 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Fibrodysplasia Ossificans Progressiva
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 5 Years to 35 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Adherence, Patient
Interventions: Immulina; Drug
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Benign Prostatic Hyperplasia, Prostate Hyperplasia, Prostate Disease, Prostate Hypertrophy, Prostate Pain, Lower Urinary Tract Symptoms, Urinary Obstruction, Urinary Tract Disease
Interventions: Finasteride; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 50 Years and older · Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acute Kidney Injury, Multiple Myeloma, Light Chain Nephropathy
Interventions: Daratumumab; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Upper Tract Urothelial Cancer
Interventions: Bladder CARE™; Diagnostic Test
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Eosinophilic Esophagitis
Interventions: Specimen Collection, Questionnaires; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2024
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Lung Cancer
Interventions: Sputum sample, Pulmonary function tests, Computerized tomography (CT) scan of the chest, Buccal epithelium collection, Nasal brushings, Bronchoscopy, Bronchoalveolar lavage, Blood sample collection, Urine sample, Questionnaire-data collection; Procedure · Radiation · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 55 Years to 80 Years
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2026
U.S. locations: 2
States / cities: Nashville, Tennessee

Conditions: Bladder Cancer
Interventions: UriFind Bladder Cancer Assay; Diagnostic Test
Lead sponsor: AnchorDx Medical Co. Ltd. US; Industry
Eligibility: 55 Years to 100 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Little Rock, Arkansas • Meridian, Idaho

Conditions: ADPKD (Autosomal Dominant Polycystic Kidney Disease)
Interventions: Bempedoic Acid 180 MG Oral Tablet, Placebo Capsule(s); Drug
Lead sponsor: Kenneth Hallows; Other
Eligibility: 18 Years to 60 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Baltimore, Maryland • Boston, Massachusetts • Burlington, Vermont

Conditions: Prostate Cancer
Interventions: ConfirmMDx, SelectMDx; Diagnostic Test
Lead sponsor: MDx Health; Industry
Eligibility: 40 Years to 85 Years · Male only
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Irvine, California

Conditions: Acute Kidney Injury
Interventions: Discarded urine sample; Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Up to 8 Years
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Intensive Care Unit Acquired Weakness (ICUAW)
Interventions: FES-Cycling, Standard Care; Device · Other
Lead sponsor: Associate Professor Sue Berney PhD, BPT; Other
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 2
States / cities: Baltimore, Maryland • Durham, North Carolina

Conditions: Ulcerative Colitis
Interventions: Urinary PGEm level, fecal calprotectin; Procedure
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Multiple Myeloma
Interventions: zoledronic acid; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 42
States / cities: Casa Grande, Arizona • La Verne, California • Los Angeles, California + 36 more

Conditions: Advanced Breast Carcinoma, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions: Biopsy, Biospecimen Collection, Laboratory Biomarker Analysis; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Neuroblastoma Survivors
Interventions: Urine sample; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Up to 20 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Neuroblastoma
Interventions: beta-glucan, monoclonal antibody 3F8, immunohistochemistry staining method, laboratory biomarker analysis; Biological · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 0 Years to 120 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Stroke, Acute Ischemic Stroke, Ischemic Stroke, Hemorrhagic Stroke
Interventions: Serum and Urine measurement of cytokines.; Other
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Urothelial Carcinoma
Interventions: Cxbladder; Other
Lead sponsor: Pacific Edge Limited; Industry
Eligibility: 18 Years and older
Enrollment: 803 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 11
States / cities: Homewood, Alabama • New Britain, Connecticut • Orlando, Florida + 7 more

Conditions: Radiation Cystitis, Urinary Tract Infection (Diagnosis)
Interventions: Hyperbaric Oxygen Therapy; Other
Lead sponsor: Rachel A. Moses; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Search by objective public record fields.

Heavy Metal Exposure in Predicting Peripheral Neuropathy in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy

Bladder Cancer Longitudinal Biorepository for Development of Novel Therapeutics/Biomarkers

Huntington's Disease Biobank: Advancing Remote Monitoring and Deep Phenotyping

EDRN Prostate MRI Biomarker Study

Urine Sample Collection From FOP Patients

Identification of Surrogate Blood and/or Urine Biomarker for Immulina TM (Trademark) in Normal Humans

5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy

Biomarkers of AKI in Patients Receiving Daratumumab

Urine Methylation Markers in UTUC

Risk Factors and Biomarkers for Diagnosis and Treatment of EoE

Nashville Early Diagnosis Lung Cancer Project

Urine Sample Collection for Validation of the AnchorDx UriFind™ Bladder Cancer Assay

Bempedoic Acid Therapy for Polycystic Kidney Disease

Prospective Validation of Prostate Biomarkers for Repeat Biopsy

Evaluation of UDP-glucose as a Urinary Biomarker for Early Detection of Cardiac Surgery-associated Pediatric Acute Kidney Injury

eStimCycle: Early Rehabilitation in Critical Care

A Study to Determine Whether Urinary PGE-M Levels Correlate With Ulcerative Colitis Disease

Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants

Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy

Biomarkers of Renal Dysfunction in Neuroblastoma Survivors

Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma

Cytokine Registry Database of Stroke Patients

The Cxbladder Monitoring Study

Chronic Radiation Cystitis and Effect of Hyperbaric Oxygen Therapy on Patient Reported Outcomes and Urine Inflammatory Biomarkers